March 5, 2020: CryoLife has announced that it has received CE mark for E-vita Open Neo, a hybrid stent graft system for the treatment of aortic arch disease. Aortic arch disease encompasses both aortic aneurysms and aortic dissections that occur unexpectedly and unwarned. Approximately 7,000 patients are diagnosed annually in Europe, the Middle East and Africa for the thoracic aortic arch disease.
Many patients with either an aneurysm or dissection in the aortic arch also have a dissected or aneurysmal thoracic aorta that descends. Such two conditions are often treated in a two-stage procedure — one for repairing the arch and the other for repairing the descending thoracic aorta.
The company’s hybrid stent-graft technology, which includes the E-vita Open Neo and the E-vita Open Plus, allows for a one-stage treatment of this condition by incorporating surgical arch repair and thoracic endovascular decay. The E-vita Open Neo is anticipated to be used regularly in conjunction with Jotec’s thoracic stent graft product, E-nya.
https://vascularnews.com/ce-mark-for-e-vita-open-neo-hybrid-stent-graft/
Your material is amazingly interesting.
Thanks for this useful information